Amalgamated Bank Cuts Stock Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Amalgamated Bank trimmed its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 28,803 shares of the specialty pharmaceutical company’s stock after selling 641 shares during the quarter. Amalgamated Bank’s holdings in Jazz Pharmaceuticals were worth $3,547,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. IFP Advisors Inc acquired a new stake in shares of Jazz Pharmaceuticals during the fourth quarter worth about $25,000. UMB Bank n.a. increased its stake in Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares during the period. Itau Unibanco Holding S.A. lifted its holdings in Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after buying an additional 172 shares in the last quarter. GAMMA Investing LLC boosted its position in Jazz Pharmaceuticals by 49.8% in the 4th quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock valued at $76,000 after buying an additional 206 shares during the period. Finally, Venturi Wealth Management LLC grew its stake in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 704 shares in the last quarter. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $143.53 on Friday. The firm has a fifty day moving average price of $126.28 and a 200 day moving average price of $118.79. The stock has a market cap of $8.68 billion, a PE ratio of 20.22, a price-to-earnings-growth ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals plc has a 1-year low of $99.06 and a 1-year high of $148.06. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74.

Analyst Ratings Changes

Several analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Royal Bank of Canada reduced their price target on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating on the stock in a research report on Wednesday. Barclays reissued an “overweight” rating and set a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday. JPMorgan Chase & Co. raised their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, Needham & Company LLC lifted their price target on shares of Jazz Pharmaceuticals from $205.00 to $210.00 and gave the stock a “buy” rating in a research note on Wednesday. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $182.47.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,500 shares of the firm’s stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $122.31, for a total transaction of $183,465.00. Following the transaction, the chief executive officer now owns 439,744 shares in the company, valued at $53,785,088.64. This trade represents a 0.34 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders sold 5,053 shares of company stock valued at $617,442. Insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.